Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase. METHODS: We randomly assigned patients with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine, who had or did not have brain metastases, to receive either tucatinib or placebo, in combination with trastuzumab and capecitabine. The primary end point was progression-free survival among the first 480 patients who underwent randomization. Secondary end points, assessed in the total population (612 patients), included overall survival, progression-free survival among patients with brain metastases, confirmed objective response rate, and safety. RESULTS: Progression-free survival at 1 year was 33.1% in the tucatinib-combination group and 12.3% in the placebo-combination group (hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.42 to 0.71; P<0.001), and the median duration of progression-free survival was 7.8 months and 5.6 months, respectively. Overall survival at 2 years was 44.9% in the tucatinib-combination group and 26.6% in the placebo-combination group (hazard ratio for death, 0.66; 95% CI, 0.50 to 0.88; P = 0.005), and the median overall survival was 21.9 months and 17.4 months, respectively. Among the patients with brain metastases, progression-free survival at 1 year was 24.9% in the tucatinib-combination group and 0% in the placebo-combination group (hazard ratio, 0.48; 95% CI, 0.34 to 0.69; P<0.001), and the median progression-free survival was 7.6 months and 5.4 months, respectively. Common adverse events in the tucatinib group included diarrhea, palmar-plantar erythrodysesthesia syndrome, nausea, fatigue, and vomiting. Diarrhea and elevated aminotransferase levels of grade 3 or higher were more common in the tucatinib-combination group than in the placebo-combination group. CONCLUSIONS: In heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, adding tucatinib to trastuzumab and capecitabine resulted in better progression-free survival and overall survival outcomes than adding placebo; the risks of diarrhea and elevated aminotransferase levels were higher with tucatinib. (Funded by Seattle Genetics; HER2CLIMB ClinicalTrials.gov number, NCT02614794.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This was achieved at the expense of increased toxicity, mostly diarrhoea and elevated aminotransferase levels of grade ≥3, but did not lead to frequent treatment discontinuation.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [62]
In the citing paper
“Tucatinib, a highly selective inhibitor of the HER2 tyrosine kinase, used in combination with capecitabine and trastuzumab in a population of ABC patients pretreated with trastuzumab, pertuzumab and trastuzumab emtansine (T-DM1), demonstrated improvement of PFS (median 7.8 months versus 5.6 months, HR 0.54; 95% CI 0.42-0.71, P < 0.001) and OS (median 21.9 months versus 17.4 months, HR 0.66; 95% CI”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [62]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network (NCCN).
Wood, E. H. (2004) · Journal of the Medical Library Association JMLA · Cited by 2,845
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationBendell, J. C., Domchek, S. M., Burstein, H. J., Harris, L., Younger, J., Kuter, I., Bunnell, C., Rue, M., Gelman, R., & Winer, E. (2003) · Cancer · doi:10.1002/cncr.11436 · Cited by 1,320
Self-citation4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationSwain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Bachelot, T., Romieu, G., Campone, M., Diéras, V., Cropet, C., Dalenc, F., Jimenez, M., Le Rhun, E., Pierga, J.-Y., Gonçalves, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70432-1 · Cited by 737
Self-citationLin, N. U., Diéras, V., Paul, D., Lossignol, D., Christodoulou, C., Stemmler, H.-J., Roché, H., Liu, M. C., Greil, R., Ciruelos, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1080 · Cited by 658
Self-citationOwens, M. A., Horten, B. C., & Da Silva, M. M. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.n.011 · Cited by 657
Research works printed but not linked: 1
- Pheneger T, Bouhana K, Anderson D, et al. In vitro and in vivo activity of ARRY-380: a potent, small molecule inhibitor of ErbB2. Cancer Res 2009;69:1795-1795. abstract.
Cited by
Items 401–500 of 1,000
Chauhan, G., Pathak, D. P., Ali, F., Dubey, P., & Khasimbi, S. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210903130152 · Cited by 21
Brain metastases: increasingly precision medicine—a narrative review
McKay, M. J. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-3665 · Cited by 18
“HER2CLIMB was a randomised Phase III trial of tucatinib in combination with capecitabine and trastuzumab, versus capecitabine/trastuzumab doublet therapy in advanced HER2+ metastatic breast cancer (75).”
BackgroundRoshankhah, R., Chen, G., Xu, Y., Butani, N., Durocher, Y., Pelton, R. H., & Ghosh, R. (2021) · Biochemical Engineering Journal · doi:10.1016/j.bej.2021.108293 · Cited by 18
Review of the diagnosis and treatment of brain metastases
Narita, Y., Sato, S., & Kayama, T. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyab182 · Cited by 19
Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies
Bergler-Klein, J. K., Rainer, P. P., Wallner, M., Zaruba, M., Dörler, J., Böhmer, A., Buchacher, T., Frey, M. K., Adlbrecht, C., Bartsch, R., et al. (2022) · Wiener klinische Wochenschrift · doi:10.1007/s00508-022-02031-0 · Cited by 20
Normann, L. S., Haugen, M. H., Aure, M. R. R., Kristensen, V. N., Mælandsmo, G. M., & Sahlberg, K. K. (2022) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s338404 · Cited by 19
Matsui, J. K., Perlow, H. K., Baiyee, C., Ritter, A. R., Mishra, M. V., Bovi, J. A., Gondi, V., Brown, P. D., Loughan, A. R., Leeper, H. E., et al. (2022) · Cancers · doi:10.3390/cancers14174301 · Cited by 19
“Patients with HER2-positive intracranial metastatic breast cancer have also benefited from targeted agents such as tucatinib combination therapy [28].”
BackgroundNovel targeted therapies for metastatic breast cancer
Jazieh, K., Bell, R., Agarwal, N., & Abraham, J. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.43 · Cited by 20
“So far, neratinib has mostly been shown to be effective in local BC (41), but there are promising results of efficacy from a phase 1b trial of patients with metastatic HER-2 positive BC treated with T-DM1 plus neratinib in patients who progressed on trastuzumab plus pertuzumab (42).”
BackgroundInfluentialCorti, C., & Criscitiello, C. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100063 · Cited by 19
“Tucatinib demonstrated efficacy compared with placebo in terms of both progression-free survival (PFS) and overall survival (OS).(2) A key unique feature of the HER2CLIMB trial was that, out of the w600 patients enrolled, 291 patients had brain metastases (BMs) at baseline.”
BackgroundMethodInfluentialThe primary sites leading to brain metastases: Shifting trends at a tertiary care center
Bhambhvani, H. P., Granucci, M., Rodrigues, A. J., Kakusa, B. W., & Gephart, M. H. (2020) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2020.08.006 · Cited by 17
ASCO 2020: highlights in breast cancer
Bartsch, R. (2021) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00674-9 · Cited by 17
Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist
Canino, F., Omarini, C., Cerma, K., Moscetti, L. I., Tornincasa, A., Trudu, L., Dominici, M., & Piacentini, F. (2022) · Clinical Breast Cancer · doi:10.1016/j.clbc.2022.02.002 · Cited by 19
Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities
Karz, A., Dimitrova, M., Kleffman, K., Alvarez-Breckenridge, C. A., Atkins, M. B., Boire, A. A., Bosenberg, M., Brastianos, P. K., Cahill, D. P., Chen, Q., et al. (2022) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13059 · Cited by 17
“…cancer have demonstrated that inhibitors designed to penetrate the blood–brain barrier (BBB) more efficiently may both effectively treat established brain metastases and prevent the development of new brain metastases (Murthy et al., 2020; Lin et al., 2020; Felip et al., 2021; Shaw et al., 2020).”
BackgroundHER2 Inhibition in Gastric Cancer—Novel Therapeutic Approaches for an Established Target
Fong, C., & Chau, I. (2022) · Cancers · doi:10.3390/cancers14153824 · Cited by 17
“Phase III data has shown that tucatinib in combination with trastuzumab and capecitabine improves progression-free and overall survival in HER2positive breast cancer patients previously treated with trastuzumab, pertuzumab and trastuzumab emtansine [88].”
BackgroundChung, C., Yeung, V. T. Y., & Wong, K. C. W. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221119797 · Cited by 17
“In metastatic disease, current anti-HER2 therapies include trastuzumab with or without pertuzumab,92–94 ado-trastuzumab emtansine,(95) fam-trastuzumab deruxtecan,(96) margetuximab,(97) lapatinib,(98) and tucatinib.(99)”
BackgroundTriple Negative Breast Cancer and Brain Metastases
Bansal, R., Swearingen, A. E. D. V., & Anders, C. K. (2023) · Clinical Breast Cancer · doi:10.1016/j.clbc.2023.07.008 · Cited by 20
Self-citationSteenbruggen, T. G., Wolf, D. M., Campbell, M. J., Sanders, J., Cornelissen, S., Thijssen, B., Salgado, R., Yau, C. S. F., O’Grady, N., Basu, A. B., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01717-1 · Cited by 17
Wallace, G. C., Kundalia, R., Vallebuona, E. J., Cao, B., Kim, Y., Forsyth, P. A., Soyano, A. E., Smalley, I., & Piña, Y. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01789-7 · Cited by 18
“Tucatinib is a newer TKI that has shown activity in HER2 + BC brain metastases, when combined with trastuzumab and capecitabine [49–51].”
BackgroundYoon, S. M., & Bazan, J. G. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01529-2 · Cited by 19
“More recently, select molecular targeted therapies primarily for HER2-positive metastatic breast cancer have reported to have variable penetration into the central nervous system (CNS) and, thus, have the ability to treat both extracranial and intracranial metastases [17, 90, 91].”
BackgroundNeuroendocrine neoplasms of the breast: a review of literature
Vegni, F., Stefano, I. S. D., Policardo, F., Tralongo, P., Feraco, A., Carlino, A., Ferraro, G., Zhang, Q., Scaglione, G., D’Alessandris, N., et al. (2024) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-024-03856-y · Cited by 19
Prevalence by therapy line and incidence of breast cancer brain metastases in 18 075 patients
Sammons, S. L., Sanglier, T., Leone, J. P., Erick, T. K., Lambert, P., Montemurro, F., Poppe, R., Restuccia, E., Tolaney, S. M., & Lin, N. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf048 · Cited by 18
Self-citationTriple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2
Shagisultanova, E. I., Crump, L. S., Borakove, M., Hall, J., Rasti, A. R., Harrison, B. A., Kabos, P., Lyons, T. R., & Borges, V. F. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0098 · Cited by 17
Self-citationSaito, A., Yoshida, H., Nishikawa, T., & Yonemori, K. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i10.868 · Cited by 18
Yin, S., Chi, Y., Du, Y., Wang, J., Shan, C., Yi, W., Shang, M., Man, X., Tan, Q., & Li, H. (2022) · Cancer Medicine · doi:10.1002/cam4.5056 · Cited by 17
Zhang, J., McAndrew, N. P., Wang, X., Du, Y., DiCarlo, B. A., Wang, M., Chen, K., Yu, W., & Hu, X. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01679-4 · Cited by 17
“Although inhibition of wild-type EGFR is a known factor associated with diarrhea and rash observed in clinical practice, tucatinib was the only HER2 inhibitor specifically designed to avoid activity against the wild-type EGFR [8].”
BackgroundInfluentialDecoding breast cancer: insights into molecular pathways & therapeutic approaches
Laskar, T. T., Laskar, H. M., Mazumder, J. A., Bhattacharjee, R., Husain, M. I., Das, B., Das, P., Choudhury, P. D., Arora, M., Borah, S., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-03764-w · Cited by 20
Lee, E. Q., Camidge, D. R., & Mehta, G. U. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349155 · Cited by 16
Current Standards and Future Outlooks in Metastatic Her2-Positive Breast Cancer
Suppan, C., & Balić, M. (2022) · Breast Care · doi:10.1159/000528756 · Cited by 16
Systemic treatments for breast cancer brain metastasis
Chen, Q., Xiong, J., Ma, Y., Wei, J., Liu, C., & Zhao, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1086821 · Cited by 19
“(34) Prospective HER2+ MBC, prior treated with trastuzumab, pertuzumab, and trastuzumab emtansine PFS, OS, ORR”
BackgroundDual attention model with reinforcement learning for classification of histology whole-slide images
Raza, M., Awan, R., Bashir, R. M. S., Qaiser, T., & Rajpoot, N. (2024) · Computerized Medical Imaging and Graphics · doi:10.1016/j.compmedimag.2024.102466 · Cited by 16
Abad, F. R. A., Pourmadadi, M., Abdouss, M., Rahdar, A., Fathi‐karkan, S., & Pandey, S. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.106902 · Cited by 23
Lee, H. J., Shin, S., Kang, J.-H., Han, K.-C., Kim, Y. H., Bae, J., & Park, K. H. (2020) · Cancers · doi:10.3390/cancers12092630 · Cited by 18
“Considering their modest efficacy and the current situation with more available antibody-drug conjugates and tyrosine kinase inhibitors [22,24], HSP90 inhibitors are not an attractive option for HER2 (+) metastatic cancers.”
BackgroundSchreiber, A., Kagihara, J. A., Weiss, J. A., Nicklawsky, A., Gao, D., Borges, V. F., Kabos, P., & Diamond, J. R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.640690 · Cited by 16
“Breast cancer is the most common cancer in women and patients with metastatic breast cancer (MBC) have a 5-year overall survival of only 27% (1).”
MethodInfluentialSelf-citationMüller, V., Wardley, A. M., Paplomata, E., Hamilton, E. P., Zelnak, A. B., Fehrenbacher, L., Jakobsen, E. H., Curtit, E., Boyle, F. M., Brix, E. H., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.05.025 · Cited by 17
“In the pivotal HER2CLIMB trial, the combination of tucatinib, trastuzumab and capecitabine became the first regimen to demonstrate a statistically significant and clinically meaningful improvement in progression-free survival and overall survival among patients with HER2þ metastatic breast cancer who progressed on tra…”
BackgroundResultInfluentialSelf-citationBreast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials
Duranti, S., Fabi, A., Filetti, M., Falcone, R., Lombardi, P., Daniele, G., Franceschini, G., Carbognin, L., Palazzo, A., Garganese, G., et al. (2021) · Cancers · doi:10.3390/cancers13205198 · Cited by 18
“Regarding safety, the tucatinib regimen caused an increase of grade ≥ 3 diarrhea and aminotransferase levels than those reported in the control group [40].”
BackgroundInfluentialAdvances in the management of breast cancer brain metastases
Sammons, S. L., Swearingen, A. E. D. V., Chung, C. D., & Anders, C. K. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab119 · Cited by 16
Self-citationEvolving management of HER2+ breast cancer brain metastases and leptomeningeal disease
Mills, M. N., King, W., Soyano, A. E., Piña, Y., Czerniecki, B. J., Forsyth, P. A., Soliman, H. H., Han, H. S., & Ahmed, K. A. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-03977-x · Cited by 16
“The phase II HER2CLIMB trial randomized patients with HER2-positive advanced breast cancer who received prior HER2-directed therapy to trastuzumab and capecitabine in combination with tucatinib or placebo [106].”
BackgroundNovel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective
Ferrario, C., Christofides, A., Joy, A. A., Laing, K. E., Gelmon, K. A., & Brezden‐Masley, C. (2022) · Current Oncology · doi:10.3390/curroncol29040222 · Cited by 17
“As a result of the improvement in outcomes for patients with brain metastases in the HER2CLIMB trial [28,37], we recommend that tucatinib + trastuzumab + capecitabine be favored as second-line treatment in patients with metastatic HER2-positive breast cancer with uncontrolled active brain metastases.”
BackgroundInfluentialSelf-citationTreatment of breast cancer brain metastases: radiotherapy and emerging preclinical approaches
Mampre, D. M., Mehkri, Y., Rajkumar, S., Sriram, S., Hernandez, J. S., Lucke-Wold, B. P., & Chandra, V. (2022) · Diagnostics and Therapeutics · doi:10.55976/dt.1202216523-36 · Cited by 17
“In a randomized trial, patients in the tucatinibcontaining arm showed longer progression-free survival (PFS) and OS [82].”
BackgroundPrecision Medicine and Distributive Justice: Wicked Problems for Democratic Deliberation
Fleck, L. M. (2022) · doi:10.1093/oso/9780197647721.001.0001 · Cited by 17
A tissue-engineered model of the blood-tumor barrier during metastatic breast cancer
Linville, R. M., Maressa, J. C., Guo, Z., Chung, T. D., Farrell, A. M., Jha, R., & Searson, P. C. (2023) · Fluids and Barriers of the CNS · doi:10.1186/s12987-023-00482-9 · Cited by 17
“Anti-HER2 IgG is a research grade biosimilar of Trastu-zumab (Herceptin ® ), which is widely used for treatment of human epidermal growth factor receptor 2 (HER2)– positive metastatic breast cancer [36].”
BackgroundMeattini, I., Andratschke, N. H., Kirby, A. M., Sviri, G. E., Offersen, B. V., Poortmans, P., & Kaidar‐Person, O. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02333-7 · Cited by 16
Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment
Foulon, A., Theret, P., Rodat‐Despoix, L., & Kischel, P. (2020) · Cancers · doi:10.3390/cancers12092634 · Cited by 18
“More recently, the association between trastuzumab + capecitabine + tucatinib has been shown to allow significant improvement of PFS in HER2+ metastatic BC patients [53].”
BackgroundMajor Strides in HER2 Blockade for Metastatic Breast Cancer
Sharma, P. (2020) · New England Journal of Medicine · doi:10.1056/nejme1916310 · Cited by 16
Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach
Adesoye, T., Dumbrava, E. E. I., Raghav, K. P. S., Şahin, A. A., Chen, H., Lee, S. S., Javle, M. M., Pant, S., Alhalabi, O., Le, X., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1982 · Cited by 21
Breast Cancer: Molecular Pathogenesis, Targeted Therapy, Screening, and Prevention
Lei, H., Fu, J., Gu, W., Qiao, H., Guo, H., Chen, Z., Wang, S. M., & Chen, T. (2026) · MedComm · doi:10.1002/mco2.70560 · Cited by 24
Li, X., Nie, P., Herdewijn, P. A., & Sun, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115928 · Cited by 15
Systemic Therapies for HER2-Positive Advanced Breast Cancer
Angelis, V., & Okines, A. F. C. (2023) · Cancers · doi:10.3390/cancers16010023 · Cited by 16
“HER2CLIMB was a pivotal randomised phase II study, in which 612 patients with HER2-positive ABC, with or without CNS metastases, were assigned 2:1 to capecitabine and trastuzumab with the addition of tucatinib or placebo [60].”
BackgroundSelf-citationLoeffler, E., Ancel, J., Dalstein, V., Deslée, G., Polette, M., & Nawrocki‐Raby, B. (2023) · Life · doi:10.3390/life14010064 · Cited by 18
“When comparing tucatinib and a placebo in combination with trastuzumab and capecitabine to treat HER2-positive breast cancer patients, the HER2 CLIMB study demonstrated that both the PFS and OS were significantly longer in the tucatinib group [128].”
BackgroundInfluence of tumor microenvironment on the different breast cancer subtypes and applied therapies
Almeida, C. F., Correia‐da‐Silva, G., Teixeira, N. A. A., & Amaral, C. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116178 · Cited by 18
Navigating the Complexities of Brain Metastases Management
Amouzegar, A., Haig, S., Kahn, A. M., Tawbi, H. A., Jones, J., & Goldberg, S. B. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_433694 · Cited by 17
Cai, A., Chen, Y., Wang, L. S., Cusick, J., & Shi, Y. H. (2024) · Cancers · doi:10.3390/cancers16152635 · Cited by 15
“Tucatinib adverse effects include elevated AST, ALT, and creatinine levels, palmar–plantar erythrodysesthesia syndrome, and diarrhea [86].”
BackgroundBartsch, R., Cameron, D., Ciruelos, E. M., Criscitiello, C., Curigliano, G., Duhoux, F. P., Foukakis, T., Gligorov, J., Harbeck, N., LeVasseur, N., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102853 · Cited by 15
Self-citationGaluia, M., Fedorova, J., McHayleh, W. M., Mamounas, E., Ahmad, S., & Pavri, S. N. (2025) · Current Oncology · doi:10.3390/curroncol32030154 · Cited by 16
“While there are currently no available data on the effect of tucatinib on wound healing (a clinical trial is ongoing) [59], the phase II study protocol required the discontinuation of tucatinib 3 to 7 days prior to surgery, and treatment was resumed 3 to 21 days postoperatively [60].”
Marwah, H., & Dewangan, H. K. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096366956250314043513 · Cited by 17
Molinelli, C., Parisi, F., Razeti, M. G., Arecco, L., Cosso, M., Fregatti, P., Mastro, L. D., Poggio, F. B., & Lambertini, M. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1857243 · Cited by 15
Nogueira, T. C. M., & Souza, M. V. N. D. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116340 · Cited by 17
Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments
Morales, S. M., Gasol, A., & Guzman, D. R. S. (2021) · Cancers · doi:10.3390/cancers13225771 · Cited by 16
“Tucatinib was evaluated in the HER2CLIMB study [66] in which patients who had progressed on a taxane, trastuzumab, pertuzumab, and T-DM1 were randomized to receive capecitabine with tucatinib and trastuzumab or capecitabine with trastuzumab.”
MethodBrain metastasis: Recent treatment modalities and future‑perspectives (Review)
Katano, A., & Yamashita, H. (2022) · Oncology Letters · doi:10.3892/ol.2022.13311 · Cited by 15
“Tucatinib, a HER2 inhibitor, improves intracranial response efficiency when included in a regimen consisting of trastuzumab and capecitabine for patients with HER2‐positive breast cancer and brain metastasis (45).”
BackgroundPyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases
Ma, X., Li, Y., Li, L., Gao, C., Liu, D., Li, H., Zhao, Z., & Zhao, B. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2139411 · Cited by 16
“Small molecule TKIs have showcased perfect efficacy in treatment of advanced BC including BM [11,21,22].”
BackgroundSharma, P., Connolly, R. M., Torres, E. T. R., & Thompson, A. M. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_281381 · Cited by 15
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020
Kayki‐Mutlu, G., & Michel, M. C. (2021) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-021-02085-3 · Cited by 16
Sun, H., Cardinal, K. A., Wienkers, L. C., Chin, A. P., Kumar, V., Neace, C., Henderson, C. M., Endres, C. J., Topletz‐Erickson, A. R., Regal, K. A., et al. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04429-z · Cited by 17
“1), is an orally bioavailable, small molecule tyrosine kinase inhibitor that is selective for HER2 (human epidermal growth factor receptor 2) over EGFR [1, 2].”
BackgroundTargeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies
Reinhorn, D. J., Moskovitz, M. T., Tap, W. D., & Li, B. T. (2025) · Cancer · doi:10.1002/cncr.35780 · Cited by 19
Hong, S., Atkinson, J. L. D., Erickson, D. Z., Kizilbash, S. H., Little, J. T., Routman, D. M., & Gompel, J. J. V. (2023) · Neurosurgical FOCUS · doi:10.3171/2023.5.focus23185 · Cited by 14
Criscitiello, C., Corti, C., Laurentiis, M. D., Bianchini, G., Pistilli, B., Cinieri, S., Castellan, L., Arpino, G., Conte, P., Meco, F. D., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102618 · Cited by 15
Self-citationKaufman, P. A., Neuberger, E. E., Schwartz, N. R. M., Wang, S., Liu, Y., Hsu, L., Bartley, K., Blahna, M. T., Pittner, B. T., Wong, G., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1264861 · Cited by 14
Self-citationJabbour, S. K., Kumar, R. N., Anderson, B. M., Chino, J., Jethwa, K. R., McDowell, L. J., Lo, A., Owen, D., Pollom, E. L., Tree, A. C., et al. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.01.010 · Cited by 14
Bartsch, R., Pérez-García, J. M., Furtner, J., Berghoff, A. S., Marhold, M., Starzer, A. M., Hughes, M. E., Kabraji, S. K., Sammons, S., Anders, C. K., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2024.104092 · Cited by 14
“10,11 Based upon results from the DESTINY-Breast03 trial, trastuzumab deruxtecan (T-DXd) is today regarded as the second-line treatment standard in patients progressing on prior trastuzumab and pertuzumab.”
Self-citationRethinking metastatic brain cancer as a CNS disease
Fares, J., Petrosyan, E., Dmello, C., Lukas, R. V., Stupp, R., & Lesniak, M. S. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00430-3 · Cited by 20
Recent Research Advances in HER2-Positive Breast Cancer Concerning Targeted Therapy Drugs
Li, J., Li, X., Fu, R., Fang, Y., Zhang, C., Ma, B., Ding, Y., Shi, C., & Zhou, Q. (2025) · Molecules · doi:10.3390/molecules30143026 · Cited by 17
“…trial, patients with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine received tucatinib + trastuzumab + capecitabine, and the results demonstrated that the median PFS extended 2.2 months and the median OS extended 4.3 months [68].”
InfluentialBallhausen, A., Wheler, J. J., Karp, D. D., Piha-Paul, S. A., Fu, S., Pant, S., Tsimberidou, A. M., Hong, D. S., Subbiah, V., Holley, V. R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2878 · Cited by 14
Lv, H., Yan, M., & Jiang, Z. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211013326 · Cited by 14
Exploring the concepts and practices of advanced breast cancer treatment: a narrative review
Wang, X., Shao, X., Huang, J., Lei, L., Huang, Y., Zheng, Y., Cao, W., & Chen, Z. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-1458 · Cited by 14
Lee, Y., Lee, M., Kim, H.-S., Kim, J., Ahn, J. S., Im, Y., & Park, Y. H. (2022) · Cancer Research and Treatment · doi:10.4143/crt.2021.1103 · Cited by 16
“positive BC [30-32], therefore better clinical outcomes are expected for HER2-positive MBC in the near future.”
BackgroundOncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review
André, L., Antherieu, G., Boinet, A., Bret, J., Gilbert, T., Boulahssass, R., & Falandry, C. (2022) · Cancers · doi:10.3390/cancers14102470 · Cited by 15
“For : [0–5%]; Cancers 20 , 14, x FOR PE R EVIEW 7 of 38 Eribulin [74, 5] 35–54 9 Ixabepilone [31] 10 nr Trastuz mab docetaxel (CLEOPATRAc) [76] 38 2 Trastuz mab paclitaxel [7 ] 8 nr Trastuz mab + oral vinorelbine [78, 9] 42 4 Trastuz mab vinorelbine v rolimus (BOLERO-3) [79] 43 12 Trastuz mab emsanti e (E ILIAi) [80]…”
MethodInfluentialRatoša, I., Dobnikar, N., Bottosso, M., Dieci, M. V., Jacot, W., Pouderoux, S., Ribnikar, D., Sinoquet, L., Guarneri, V., Žnidarič, T., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34135 · Cited by 14
Schlam, I. M., Nunes, R., & Lynce, F. C. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s272197 · Cited by 14
“The tyrosine kinase inhibitors (TKI) neratinib and tucatinib (in combination with capecitabine and/or trastuzumab) were approved based on the NALA and HER2CLIMB studies, respectively.(6,12) Finally, the Fc-engineered immune activating anti-ERBB2 IgG1 immunoglobulin margetuximab was approved by the US Food and Drug Adm…”
MethodGermline Testing in Prostate Cancer: When and Who to Test
Sokolova, A. O. (2021) · ONCOLOGY · doi:10.46883/onc.2021.3510.0645 · Cited by 14
Liu, X., Chipurupalli, S., Jiang, P., Tavasoli, M., Yoo, B. H., McPhee, M. J., Mazinani, S. A., Francia, G., Kerbel, R. S., & Rosen, K. V. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05117-9 · Cited by 14
“Approximately 20% of such malignancies develop resistance to these agents and become incurable [2, 3].”
BackgroundGonullu, B., Angeli, E., Pamoukdjian, F., & Bousquet, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043590 · Cited by 14
Khatri, V. M., Mills, M. N., Oliver, D. E., Yu, H.-H. M., Vogelbaum, M. A., Forsyth, P. A., Soliman, H. H., Han, H. S., & Ahmed, K. A. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04402-7 · Cited by 15
Li, L., Zhang, D., Wu, Y., Wang, J., & Ma, F. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188969 · Cited by 16
Chipurupalli, S., Jiang, P., Liu, X., Santos, J. L., Marcato, P., & Rosen, K. V. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06106-2 · Cited by 15
“Patients with trastuzumab-resistant tumors invariably die of BC [28].”
BackgroundNakano, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316823 · Cited by 16
“Tucatinib is prescribed in combination with capecitabine and trastuzumab, and it has demonstrated a promising effect on brain metastases [25,26].”
BackgroundMichel, L. L., Hartkopf, A. D., Fasching, P. A., Kolberg, H., Hadji, P., Tesch, H., Häberle, L., Ettl, J., Lüftner, D., Wallwiener, M., et al. (2020) · Cancers · doi:10.3390/cancers12103021 · Cited by 14
“5 months) compared to trastuzumab and capecitabine alone [25].”
BackgroundSelf-citationCan Women With HER2-Positive Metastatic Breast Cancer Be Cured?
Haji, F., & Hurvitz, S. A. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.06.012 · Cited by 14
Self-citationTargeted Therapies in Older Adults With Solid Tumors
Battisti, N. M. L., Decoster, L., Williams, G. R., Kanesvaran, R., Wildiers, H., & Ring, A. E. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00132 · Cited by 14
Hurvitz, S. A., Loi, S., O’Shaughnessy, J., Okines, A. F. C., Tolaney, S. M., Sohn, J., Saura, C., Zhu, X., Cameron, D., Bachelot, T., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.11.005 · Cited by 17
Self-citationPeterson, L. E. (2020) · African Journal of Pharmaceutical Sciences · doi:10.2139/ssrn.3580951 · Cited by 13
Transglutaminase-2 mediates acquisition of neratinib resistance in metastatic breast cancer
Shinde, A. B., Kulkoyluoglu‐Cotul, E., Chen, H., Smith, A. J., Libring, S., Solorio, L., & Wendt, M. K. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00079-y · Cited by 13
“The enhanced specificity of these compounds for HER2 decreases systemic toxicities [35].”
BackgroundMarie, L., Braik, D., Abdel-Razeq, N., Abu‐Fares, H., Al-Thunaibat, A., & Abdel‐Razeq, H. (2022) · Cancer Management and Research · doi:10.2147/cmar.s369910 · Cited by 14
Long-term survival in patients with brain metastases—clinical characterization of a rare scenario
Hügel, M., Stöhr, J., Kuhnt, T., Nägler, F., Papsdorf, K., Klagges, S., Hambsch, P. K., Güresir, E., Nicolay, N. H., & Seidel, C. (2023) · Strahlentherapie und Onkologie · doi:10.1007/s00066-023-02123-4 · Cited by 20
“More recently, other substances like tucatinib [44] or antibody–drug conjugates like trastuzumab deruxtecan [45–47] proved to be active in BM.”
BackgroundYan, M., Ouyang, Q., Sun, T., Niu, L., Yang, J., Li, L., Song, Y., Hao, C., Chen, Z., Liu, Z., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102837 · Cited by 13
Guglielmi, G., Zamagni, C., Re, M. D., Danesi, R., & Fogli, S. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177076 · Cited by 14
Quantum DFT analysis and molecular docking investigation of various potential breast cancer drugs
Ayub, M. A., Tyagi, A. R., Srivastava, S. K., & Singh, P. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb01803f · Cited by 16
Erickson, A. W., Ghodrati, F., Habbous, S., Jerzak, K. J., Sahgal, A., Ahluwalia, M. S., & Das, S. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa136 · Cited by 13
Yokoe, T., Kurozumi, S., Nozawa, K., Ozaki, Y., Maeda, T., Yazaki, S., Onishi, M., Fujimoto, A., Nakayama, S., Tsuboguchi, Y., et al. (2021) · Breast Cancer · doi:10.1007/s12282-020-01192-y · Cited by 14
Dong, L., Lin, S., Zhong, L., Nian, D., Li, Y., Wang, R., Zhou, W., Weng, X., & Xu, X. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.06.001 · Cited by 13
US Food and Drug Administration regulatory updates in neuro-oncology
Mehta, G. U., Barone, A. K., Bradford, D., Larkins, E. A., Kim, J., Pai-Scherf, L. H., Jaigirdar, A. A., Shah, M., Wedam, S. B., Amiri‐Kordestani, L., et al. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-021-03789-5 · Cited by 13
Metadata
- Authors
- Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., Bedard, P. L., Oliveira, M., Jakobsen, E., Bachelot, T., Shachar, S. S., Müller, V., Braga, S., Duhoux, F. P., Greil, R., Cameron, D., Carey, L. A., Curigliano, G., Gelmon, K., Hortobagyi, G., Krop, I., Loibl, S., Pegram, M., Slamon, D., Palanca-Wessels, M. C., Walker, L., Feng, W., & Winer, E. P.
- Affiliations
- Royal Marsden NHS Foundation Trust (GB)
- From M.D. Anderson Cancer Center, Houston (R.K.M., G.H.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S. Loi); the Royal Marsden NHS Foundation Trust, London (A.O.), and Edinburgh Cancer Research Centre, Edinburgh (D.C.) — both in the United Kingdom; Winship Cancer Institute, Atlanta (E.P.); Sarah Cannon Research Institute/Tennessee Oncology–Nashville (E.H.) and Vanderbilt University Medical Center (V.A.), Nashville; University of California, Los Angeles, Medical Center–Jonsson...
- BC Cancer Agency (CA)
- ORCID
- Murthy, Rashmi K.
- Loi, Sherene
- Okines, Alicia
- Hamilton, Erika
- Hurvitz, Sara A.
- Borges, Virginia
- Abramson, Vandana
- Anders, Carey
- Bedard, Philippe L.
- Oliveira, Mafalda
- Jakobsen, Erik
- Bachelot, Thomas
- Shachar, Shlomit S.
- Müller, Volkmar
- Braga, Sofia
- Duhoux, Francois P.
- Greil, Richard
- Cameron, David
- Curigliano, Giuseppe
- Gelmon, Karen
- Krop, Ian
- Loibl, Sibylle
- Pegram, Mark
- Slamon, Dennis
- Palanca-Wessels, M. Corinna
- Feng, Wentao
- Winer, Eric P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-13
- Volume
- 382
- Issue
- 7
- Pages
- 597-609
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2995808512
- Cited by
- 1,326
- References
- 29
- Citations by year
- 2026: 118 · 2025: 158 · 2024: 203 · 2023: 197 · 2022: 252 · 2021: 244 · 2020: 152
- FWCI
- 67.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- UNC Libraries
- Funders
- Seattle Genetics
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- tucatinib, HER2-positive metastatic breast cancer, trastuzumab, capecitabine, HER2 tyrosine kinase inhibitor, brain metastases, progression-free survival, overall survival, pertuzumab, trastuzumab emtansine, HER2-targeted therapy, diarrhea, hand-foot syndrome
- MeSH terms
- Trastuzumab, Capecitabine, Progression-Free Survival, Aged, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Breast Neoplasms, Diarrhea, Double-Blind Method, Female, Humans, Middle Aged, Oxazoles, Protein-Tyrosine Kinases, Pyridines, Quinazolines, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Kaplan-Meier Estimate, Consolidation Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.